First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Gettinger, Scott N
  • Hellmann, Matthew David
  • Shepherd, Frances A
  • Antonia, Scott Joseph
  • Brahmer, Julie R
  • Chow, Laura Quan Man
  • Goldman, Jonathan Wade
  • Juergens, Rosalyn
  • Borghaei, Hossein
  • Ready, Neal
  • Gerber, David E
  • Nathan, Faith Ellen
  • Shen, Yun
  • Harbison, Christopher
  • Rizvi, Naiyer A

publication date

  • May 20, 2015